Cancer: Modeling glioblastoma
Establishing a zebrafish model of a deadly type of brain tumor highlights the role of the immune system in the early stages of the disease.
- Ottawa Hospital Research Institute, Canada
- Departments of Medicine and Biochemistry, Microbiology and Immunology, University of Ottawa, Canada
Glioblastoma is the most common type of brain cancer in adults. Patients initially have relatively non-specific symptoms such as headaches, nausea and cognitive changes. Their diagnostic journey usually involves undergoing magnetic resonance imaging (MRI) of the brain, as this approach is highly effective at distinguishing glioblastoma from other conditions with similar symptoms. When the scan shows that glioblastoma is likely, patients typically undergo surgery; a definitive diagnosis comes from the examination of a surgical sample by a pathologist.
This dry clinical description glosses over the human and emotional toll of the disease. Patients quickly learn that while surgery can be helpful, it is never curative, and that radiation and chemotherapy have limited benefits and may also have serious side effects. Around half of glioblastoma patients die within 15 months of their diagnosis, and only about 5% are still alive after five years (Stupp et al., 2005). This cancer is a brutal disease that seems to come out of nowhere.
Glioblastoma is currently being intensively studied worldwide. Advanced genetic analyses have allowed researchers to better identify the mutations that contribute to the emergence of this cancer, as well as the different types of cells forming the tumor and the various ‘states’ they can adopt (Abdelfattah et al., 2022; Brennan et al., 2013; Neftel et al., 2019). However, a clear understanding of the very early stages of the disease has remained elusive. Now, in eLife, Alex Weiss, Cassandra D'Amata, Bret Pearson and Madeline Hayes report having established a zebrafish model of glioblastoma that provides insight into this critical period (Weiss et al., 2024).
Zebrafish are small animals that reproduce fast and are easy to raise in the laboratory. They are also naturally transparent early in development, allowing researchers to use microscopy techniques to observe cellular interactions in real time. Their genes are well-studied and can therefore be matched to their human counterparts based on sequence similarities, meaning findings made in this animal model could be translated into discoveries relevant to patients.
The team (who are based at the Hospital for Sick Children in Toronto, the University of Toronto and Oregon Health & Science University) worked with a line of zebrafish lacking a protein called TP53 that normally suppresses tumor development but is commonly inactivated in glioblastomas. The animals were genetically engineered so that mutated genes known to drive the emergence of glioblastoma were expressed in their neural progenitors, the cell type from which this cancer usually originates. This included two oncogenes, EGFRvIII and PIK3CAH1047R, which prompt ‘rogue’ cells to multiply and invade healthy tissues. As a result, the fish reliably developed tumors similar to those found in glioblastoma patients. Notably, the experiments revealed a characteristic pattern of gene expression associated with inflammation, which has also been observed in human glioblastoma (Richards et al., 2021).
This result prompted Weiss et al. to investigate which immune cells were present in zebrafish tumors, with a focus on microglia, the resident macrophages of the brain. These cells are very abundant in human glioblastoma samples taken from large, established tumors, where they have an immunosuppressive role (Lee et al., 2021). In established zebrafish tumors, infiltrating microglia were readily detected. The cells adopted a rounded, ‘activated’ morphology and were observed to be engulfing and digesting glioblastoma cells, as they do in the human version of the disease (Penfield, 1925). Excitingly, Weiss et al. were able to show that microglia were present and active not only when a zebrafish tumor was well-established but also when it had just started to grow.
The team then aimed to assess the role of microglia in early glioblastoma using two different approaches. In the first set of experiments, precisely deleting one of two genes involved in the immune response – one required for macrophage and microglia development, the other for mediating inflammatory responses – resulted in tumors being more likely to form. Next, Weiss et al. introduced cells from zebrafish glioblastomas into healthy zebrafish embryos. When the transplanted embryos were administered clodronate, a drug that destroys microglia, their risk of growing tumors increased. Taken together, these findings suggest that these immune cells help suppress the development of the cancer early on (Figure 1B).
Figure 1
Different roles for microglia in late-stage and early-stage glioblastoma.
(A) Analyses of late-stage glioblastoma tumors show that, along with tumor cells (yellow, with nuclei shown in blue), large numbers of microglia (orange, with nuclei shown in blue) are also present. Microglia in the normal brain have multiple long extensions (bottom cells with blue extensions). Upon recruitment into tumors (orange arrows), these are lost, and the cells adopt a rounder morphology. Late-stage glioblastoma tumors also develop new blood vessels (pink ellipse with white rim) from which they recruit macrophages (dark red). Microglia and macrophages engage in phagocytosis within the tumor (orange cells with red border), engulfing and digesting rogue cells. Multiple studies have shown that microglia are immunosuppressive and tumor-promoting in this context. (B) Weiss et al. used their zebrafish model to show that microglia are also recruited in the early stages of the disease, during which the cells also engage in phagocytosis. During this period, however, these cells do not help to suppress the immune system; instead, they increase the inflammatory response, and their depletion enhances glioblastoma development.
Current cancer therapies that rely on prompting the immune system to attack tumors are largely ineffective for glioblastoma (Reardon et al., 2020). This study points to a different role for microglia in the early stages of the cancer, when they actively repress tumor formation. Further studies are needed to uncover how these immune cells shift from suppressing to promoting the growth of this cancer as it develops. This knowledge may provide new avenues to develop effective glioblastoma immunotherapy and offer new hope to patients and their families.
References
-
Microglia and the process of phagocytosis in gliomasThe American Journal of Pathology 1:77–90.
-
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastomaThe New England Journal of Medicine 352:987–996.https://doi.org/10.1056/NEJMoa043330
Article and author information
Author details
Publication history
Copyright
© 2024, Lorimer
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 704
- views
-
- 73
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Cancer: Modeling glioblastoma
eLife 13:e100824.
https://doi.org/10.7554/eLife.100824
Further reading
-
- Cancer Biology
- Chromosomes and Gene Expression
Despite exciting developments in cancer immunotherapy, its broad application is limited by the paucity of targetable antigens on the tumor cell surface. As an intrinsic cellular pathway, nonsense-mediated decay (NMD) conceals neoantigens through the destruction of the RNA products from genes harboring truncating mutations. We developed and conducted a high-throughput screen, based on the ratiometric analysis of transcripts, to identify critical mediators of NMD in human cells. This screen implicated disruption of kinase SMG1’s phosphorylation of UPF1 as a potential disruptor of NMD. This led us to design a novel SMG1 inhibitor, KVS0001, that elevates the expression of transcripts and proteins resulting from human and murine truncating mutations in vitro and murine cells in vivo. Most importantly, KVS0001 concomitantly increased the presentation of immune-targetable human leukocyte antigens (HLA) class I-associated peptides from NMD-downregulated proteins on the surface of human cancer cells. KVS0001 provides new opportunities for studying NMD and the diseases in which NMD plays a role, including cancer and inherited diseases.
-
- Cancer Biology
- Medicine
A doctoral-level internship program was developed at the University of North Carolina at Chapel Hill with the intent to create customizable experiential learning opportunities for biomedical trainees to support career exploration, preparation, and transition into their postgraduate professional roles. We report the outcomes of this program over a 5-year period. During that 5-year period, 123 internships took place at over 70 partner sites, representing at least 20 academic, for-profit, and non-profit career paths in the life sciences. A major goal of the program was to enhance trainees’ skill development and expertise in careers of interest. The benefits of the internship program for interns, host/employer, and supervisor/principal investigator were assessed using a mixed-methods approach, including surveys with closed- and open-ended responses as well as focus group interviews. Balancing stakeholder interests is key to creating a sustainable program with widespread support; hence, the level of support from internship hosts and faculty members were the key metrics analyzed throughout. We hypothesized that once a successful internship program was implemented, faculty culture might shift to be more accepting of internships; indeed, the data quantifying faculty attitudes support this. Furthermore, host motivation and performance expectations of interns were compared with results achieved, and this data revealed both expected and surprising benefits to hosts. Data suggests a myriad of benefits for each stakeholder group, and themes are cataloged and discussed. Program outcomes, evaluation data, policies, resources, and best practices developed through the implementation of this program are shared to provide resources that facilitate the creation of similar internship programs at other institutions. Program development was initially spurred by National Institutes of Health pilot funding, thereafter, successfully transitioning from a grant-supported model, to an institutionally supported funding model to achieve long-term programmatic sustainability.
